{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:32:47Z","timestamp":1791772367642,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>\n                    <jats:italic>Abstract<\/jats:italic>\n                  <\/jats:title>\n                  <jats:p>\n                    Treatment of cancer cachexia remains an unmet need. The host-tumour interface and the resulting sequestration of the pro-inflammatory cytokine Il-1\u03b2 is critical in cachexia development. Neuroinflammation mediated\n                    <jats:italic>via<\/jats:italic>\n                    IL-1\u03b2 through the hypothalamic pituitary axis results in increased muscle proteolysis and adipose lipolysis, thus creating a prolonged stress-like environment with loss of appetite and increased resting energy expenditure. Recent trials using a monoclonal antibody targeting IL-1\u03b2, canakinumab, have shown a potential role in lung cancer; however, a potential role of targeting IL-1\u03b2 to treat cachexia in patients with lung cancer is unclear, yet the underlying pathophysiology provides a sound rationale that this may be a viable therapeutic approach.\n                  <\/jats:p>","DOI":"10.1007\/s10753-021-01429-8","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T12:04:26Z","timestamp":1619525066000},"page":"1223-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["The Emerging Role of Interleukin 1\u03b2 (IL-1\u03b2) in Cancer Cachexia"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-6192","authenticated-orcid":false,"given":"Barry J.","family":"Laird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J. E.","family":"Skipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Robert","family":"Paval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"1429_CR1","unstructured":"Organization WH. Cancer fact sheet. 2017 [Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs297\/.en."},{"key":"1429_CR2","doi-asserted-by":"crossref","unstructured":"Daly, L., R. Dolan, D. Power, E. Ni Bhuachalla, W. Sim, M. Fallon, et al. 2019. The relationship between the BMI-adjusted weight loss grading system and quality of life in patients with incurable cancer. Journal of Cachexia, Sarcopenia and Muscle.","DOI":"10.1002\/jcsm.12499"},{"issue":"10","key":"1429_CR3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","volume":"90","author":"PJ Ross","year":"2004","unstructured":"Ross, P.J., S. Ashley, A. Norton, K. Priest, J.S. Waters, T. Eisen, I.E. Smith, and M.E.R. O'Brien. 2004. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? British Journal of Cancer 90 (10): 1905\u20131911.","journal-title":"British Journal of Cancer"},{"issue":"9","key":"1429_CR4","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/annonc\/mdx345","volume":"28","author":"B Laird","year":"2017","unstructured":"Laird, B., and M. Fallon. 2017. Treating cancer cachexia: An evolving landscape. Annals of Oncology 28 (9): 2055\u20132056.","journal-title":"Annals of Oncology"},{"issue":"4","key":"1429_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel, J.S., A.P. Abernethy, D.C. Currow, J. Friend, E.M. Duus, Y. Yan, and K.C. Fearon. 2016. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. The Lancet Oncology 17 (4): 519\u2013531.","journal-title":"The Lancet Oncology"},{"key":"1429_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13539-014-0129-y","volume":"5","author":"J Crawford","year":"2014","unstructured":"Crawford, J., J.T. Dalton, M.L. Hancock, M.A. Johnston, and M.S. Steiner. 2014. Enobosarm, a selective androgen receptor modulator (SARM) increases Lean body mass (LBM) in advanced non-small cell lung cancer patients in two pivotal international phase 3 trials. J Cachexia Sarcopenia Muscle 5: 35.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"1429_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K., F. Strasser, S.D. Anker, I. Bosaeus, E. Bruera, R.L. Fainsinger, A. Jatoi, C. Loprinzi, N. MacDonald, G. Mantovani, M. Davis, M. Muscaritoli, F. Ottery, L. Radbruch, P. Ravasco, D. Walsh, A. Wilcock, S. Kaasa, and V.E. Baracos. 2011. Definition and classification of cancer cachexia: An international consensus. The Lancet Oncology 12 (5): 489\u2013495.","journal-title":"The Lancet Oncology"},{"issue":"5","key":"1429_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends, J., V. Baracos, H. Bertz, F. Bozzetti, P.C. Calder, N.E.P. Deutz, N. Erickson, A. Laviano, M.P. Lisanti, D.N. Lobo, D.C. McMillan, M. Muscaritoli, J. Ockenga, M. Pirlich, F. Strasser, M. de van der Schueren, A. van Gossum, P. Vaupel, and A. Weimann. 2017. ESPEN expert group recommendations for action against cancer-related malnutrition. Clinical Nutrition 36 (5): 1187\u20131196.","journal-title":"Clinical Nutrition"},{"key":"1429_CR9","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos, V.E., L. Martin, M. Korc, D.C. Guttridge, and K.C.H. Fearon. 2018. Cancer-associated cachexia. Nature Reviews. Disease Primers 4: 17105.","journal-title":"Nature Reviews. Disease Primers"},{"issue":"11","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos, C.I., K.A. Charles, D.C. McMillan, and S.J. Clarke. 2014. Cancer-related inflammation and treatment effectiveness. The Lancet Oncology 15 (11): e493\u2013e503.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","volume":"36","author":"T Cederholm","year":"2017","unstructured":"Cederholm, T., R. Barazzoni, P. Austin, P. Ballmer, G. Biolo, S.C. Bischoff, C. Compher, I. Correia, T. Higashiguchi, M. Holst, G.L. Jensen, A. Malone, M. Muscaritoli, I. Nyulasi, M. Pirlich, E. Rothenberg, K. Schindler, S.M. Schneider, M.A.E. de van der Schueren, C. Sieber, L. Valentini, J.C. Yu, A. van Gossum, and P. Singer. 2017. ESPEN guidelines on definitions and terminology of clinical nutrition. Clinical Nutrition 36 (1): 49\u201364.","journal-title":"Clinical Nutrition"},{"issue":"1","key":"1429_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jcsm.12383","volume":"10","author":"T Cederholm","year":"2019","unstructured":"Cederholm, T., G.L. Jensen, M. Correia, M.C. Gonzalez, R. Fukushima, T. Higashiguchi, et al. 2019. GLIM criteria for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community. Journal of Cachexia, Sarcopenia and Muscle 10 (1): 207\u2013217.","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"1429_CR13","doi-asserted-by":"crossref","unstructured":"Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017.","DOI":"10.1002\/jcsm.12201"},{"key":"1429_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","volume":"132","author":"R Dolan","year":"2018","unstructured":"Dolan, R., B. Laird, P.G. Horgan, and D.C. McMillan. 2018. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review. Critical Reviews in Oncology\/Hematology 132: 130\u2013137.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"1429_CR15","unstructured":"MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative\/supportive care. J Support Oncol. 2007;5(4):157\u201362; discussion 64\u20136, 83."},{"issue":"10","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1200\/JCO.1995.13.10.2600","volume":"13","author":"AJ Staal-van den Brekel","year":"1995","unstructured":"Staal-van den Brekel, A.J., M.A. Dentener, A.M. Schols, W.A. Buurman, and E.F. Wouters. 1995. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. Journal of Clinical Oncology 13 (10): 2600\u20132605.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"1429_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MCO.0b013e32832a7902","volume":"12","author":"DC McMillan","year":"2009","unstructured":"McMillan, D.C. 2009. Systemic inflammation, nutritional status and survival in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care 12 (3): 223\u2013226.","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"issue":"23","key":"1429_CR18","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.2015.65.7742","volume":"34","author":"BJ Laird","year":"2016","unstructured":"Laird, B.J., M. Fallon, M.J. Hjermstad, S. Tuck, S. Kaasa, P. Klepstad, et al. 2016. Quality of life in patients with advanced cancer: Differential association with performance status and systemic inflammatory response. Journal of Clinical Oncology 34 (23): 2769\u20132775.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"1429_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.lungcan.2015.03.020","volume":"88","author":"CP Simmons","year":"2015","unstructured":"Simmons, C.P., F. Koinis, M.T. Fallon, K.C. Fearon, J. Bowden, T.S. Solheim, B.H. Gronberg, D.C. McMillan, I. Gioulbasanis, and B.J. Laird. 2015. Prognosis in advanced lung cancer--a prospective study examining key clinicopathological factors. Lung Cancer 88 (3): 304\u2013309.","journal-title":"Lung Cancer"},{"issue":"2","key":"1429_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1207\/S15327914NC352_5","volume":"35","author":"P O'Gorman","year":"1999","unstructured":"O'Gorman, P., D.C. McMillan, and C.S. McArdle. 1999. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutrition and Cancer 35 (2): 127\u2013129.","journal-title":"Nutrition and Cancer"},{"issue":"1","key":"1429_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bjc.6604828","volume":"100","author":"DA Deans","year":"2009","unstructured":"Deans, D.A., B.H. Tan, S.J. Wigmore, J.A. Ross, A.C. de Beaux, S. Paterson-Brown, et al. 2009. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. British Journal of Cancer 100 (1): 63\u201369.","journal-title":"British Journal of Cancer"},{"issue":"5","key":"1429_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jcsm.12220","volume":"8","author":"OM Vagnildhaug","year":"2017","unstructured":"Vagnildhaug, O.M., D. Blum, A. Wilcock, P. Fayers, F. Strasser, V.E. Baracos, M.J. Hjermstad, S. Kaasa, B. Laird, T.S. Solheim, and for the European Palliative Care Cancer Symptom study group. 2017. The applicability of a weight loss grading system in cancer cachexia: A longitudinal analysis. Journal of Cachexia, Sarcopenia and Muscle 8 (5): 789\u2013797.","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"1429_CR23","unstructured":"Magne OM, Blum D, Wilcock A, Fayers P, Strasser F, Baracos V, et al. The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis. Journal of Cachexia, Sarcopenia and Muscle. 2017;In press."},{"issue":"9","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1634\/theoncologist.2013-0120","volume":"18","author":"BJ Laird","year":"2013","unstructured":"Laird, B.J., D.C. McMillan, P. Fayers, K. Fearon, S. Kaasa, M.T. Fallon, et al. 2013. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist. 18 (9): 1050\u20131055.","journal-title":"Oncologist."},{"key":"1429_CR25","unstructured":"Simmons CPL, McMillan DC, Tuck S, Graham C, McKeown A, Bennett MI, et al. Comparison of validated prognostic factors in patients with advanced cancer: a prospective cohort study Under consideration2019."},{"issue":"19","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-13-1066","volume":"19","author":"BJ Laird","year":"2013","unstructured":"Laird, B.J., S. Kaasa, D.C. McMillan, M.T. Fallon, M.J. Hjermstad, P. Fayers, et al. 2013. Prognostic factors in patients with advanced cancer: A comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clinical Cancer Research 19 (19): 5456\u20135464.","journal-title":"Clinical Cancer Research"},{"key":"1429_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2015.03.015","volume":"80","author":"P Londhe","year":"2015","unstructured":"Londhe, P., and D.C. Guttridge. 2015. Inflammation induced loss of skeletal muscle. Bone. 80: 131\u2013142.","journal-title":"Bone."},{"issue":"8","key":"1429_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello, C.A., A. Simon, and J.W. van der Meer. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews. Drug Discovery 11 (8): 633\u2013652.","journal-title":"Nature Reviews. Drug Discovery"},{"key":"1429_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-38315-2_1","volume":"1240","author":"W Zhang","year":"2020","unstructured":"Zhang, W., N. Borcherding, and R. Kolb. 2020. IL-1 signaling in tumor microenvironment. Advances in Experimental Medicine and Biology 1240: 1\u201323.","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"1429_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imr.12614","volume":"281","author":"A Mantovani","year":"2018","unstructured":"Mantovani, A., I. Barajon, and C. Garlanda. 2018. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunological Reviews 281 (1): 57\u201361.","journal-title":"Immunological Reviews"},{"issue":"37","key":"1429_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017019","volume":"97","author":"R Dolan","year":"2019","unstructured":"Dolan, R., B. Laird, P. Klepstad, S. Kaasa, P. Horgan, O. Paulsen, et al. 2019. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine. 97 (37): e17019.","journal-title":"Medicine."},{"issue":"2","key":"1429_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ajcn.70.2.183","volume":"70","author":"SS Yeh","year":"1999","unstructured":"Yeh, S.S., and M.W. Schuster. 1999. Geriatric cachexia: The role of cytokines. The American Journal of Clinical Nutrition 70 (2): 183\u2013197.","journal-title":"The American Journal of Clinical Nutrition"},{"issue":"10","key":"1429_CR33","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0899-9007(96)00164-5","volume":"12","author":"A Laviano","year":"1996","unstructured":"Laviano, A., M.M. Meguid, Z.J. Yang, J.R. Gleason, C. Cangiano, and Fanelli F. Rossi. 1996. Cracking the riddle of cancer anorexia. Nutrition. 12 (10): 706\u2013710.","journal-title":"Nutrition."},{"issue":"9","key":"1429_CR34","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1210\/en.2007-0017","volume":"148","author":"JM Scarlett","year":"2007","unstructured":"Scarlett, J.M., E.E. Jobst, P.J. Enriori, D.D. Bowe, A.K. Batra, W.F. Grant, M.A. Cowley, and D.L. Marks. 2007. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology. 148 (9): 4217\u20134225.","journal-title":"Endocrinology."},{"issue":"10","key":"1429_CR35","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1210\/en.2007-1680","volume":"149","author":"JM Scarlett","year":"2008","unstructured":"Scarlett, J.M., X. Zhu, P.J. Enriori, D.D. Bowe, A.K. Batra, P.R. Levasseur, W.F. Grant, M.M. Meguid, M.A. Cowley, and D.L. Marks. 2008. Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology. 149 (10): 4837\u20134845.","journal-title":"Endocrinology."},{"issue":"4","key":"1429_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1210\/en.2002-221099","volume":"144","author":"DL Marks","year":"2003","unstructured":"Marks, D.L., A.A. Butler, R. Turner, G. Brookhart, and R.D. Cone. 2003. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology. 144 (4): 1513\u20131523.","journal-title":"Endocrinology."},{"issue":"2","key":"1429_CR37","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1523\/JNEUROSCI.14-02-00897.1994","volume":"14","author":"A Ericsson","year":"1994","unstructured":"Ericsson, A., K.J. Kovacs, and P.E. Sawchenko. 1994. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. The Journal of Neuroscience 14 (2): 897\u2013913.","journal-title":"The Journal of Neuroscience"},{"issue":"12","key":"1429_CR38","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1084\/jem.20111020","volume":"208","author":"TP Braun","year":"2011","unstructured":"Braun, T.P., X. Zhu, M. Szumowski, G.D. Scott, A.J. Grossberg, P.R. Levasseur, K. Graham, S. Khan, S. Damaraju, W.F. Colmers, V.E. Baracos, and D.L. Marks. 2011. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. The Journal of Experimental Medicine 208 (12): 2449\u20132463.","journal-title":"The Journal of Experimental Medicine"},{"issue":"3","key":"1429_CR39","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/0008-5472.CAN-06-2956","volume":"67","author":"Y Krelin","year":"2007","unstructured":"Krelin, Y., E. Voronov, S. Dotan, M. Elkabets, E. Reich, M. Fogel, M. Huszar, Y. Iwakura, S. Segal, C.A. Dinarello, and R.N. Apte. 2007. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Research 67 (3): 1062\u20131071.","journal-title":"Cancer Research"},{"key":"1429_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/SPC.0000000000000398","volume":"12","author":"JJ McDonald","year":"2018","unstructured":"McDonald, J.J., D.C. McMillan, and B.J. Laird. 2018. Targeting IL-1alpha in cancer cachexia: A narrative review. Current Opinion in Supportive and Palliative Care 12: 453\u2013459.","journal-title":"Current Opinion in Supportive and Palliative Care"},{"issue":"Suppl 1","key":"1429_CR41","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.2119\/molmed.2014.00232","volume":"20","author":"CA Dinarello","year":"2014","unstructured":"Dinarello, C.A. 2014. An expanding role for interleukin-1 blockade from gout to cancer. Molecular Medicine 20 (Suppl 1): S43\u2013S58.","journal-title":"Molecular Medicine"},{"key":"1429_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-7-45","volume":"7","author":"D Zhang","year":"2007","unstructured":"Zhang, D., H. Zheng, Y. Zhou, X. Tang, B. Yu, and J. Li. 2007. Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer 7: 45.","journal-title":"BMC Cancer"},{"issue":"1","key":"1429_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0167-5273(02)00235-8","volume":"85","author":"KC Fearon","year":"2002","unstructured":"Fearon, K.C., and A.G. Moses. 2002. Cancer cachexia. International Journal of Cardiology 85 (1): 73\u201381.","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"1429_CR44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00423-004-0486-7","volume":"389","author":"MJ Tisdale","year":"2004","unstructured":"Tisdale, M.J. 2004. Cancer cachexia. Langenbeck's Archives of Surgery 389 (4): 299\u2013305.","journal-title":"Langenbeck's Archives of Surgery"},{"issue":"3","key":"1429_CR45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1172\/JCI200420174","volume":"114","author":"S Acharyya","year":"2004","unstructured":"Acharyya, S., K.J. Ladner, L.L. Nelsen, J. Damrauer, P.J. Reiser, S. Swoap, and D.C. Guttridge. 2004. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. The Journal of Clinical Investigation 114 (3): 370\u2013378.","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"1429_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clnu.2011.07.010","volume":"31","author":"C Scheede-Bergdahl","year":"2012","unstructured":"Scheede-Bergdahl, C., H.L. Watt, B. Trutschnigg, R.D. Kilgour, A. Haggarty, E. Lucar, and A. Vigano. 2012. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clinical Nutrition 31 (1): 85\u201388.","journal-title":"Clinical Nutrition"},{"issue":"2","key":"1429_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1210\/en.2009-1135","volume":"151","author":"AJ Grossberg","year":"2010","unstructured":"Grossberg, A.J., J.M. Scarlett, X. Zhu, D.D. Bowe, A.K. Batra, T.P. Braun, and D.L. Marks. 2010. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology. 151 (2): 606\u2013616.","journal-title":"Endocrinology."},{"issue":"4","key":"1429_CR48","first-page":"1432","volume":"61","author":"DL Marks","year":"2001","unstructured":"Marks, D.L., N. Ling, and R.D. Cone. 2001. Role of the central melanocortin system in cachexia. Cancer Research 61 (4): 1432\u20131438.","journal-title":"Cancer Research"},{"issue":"12","key":"1429_CR49","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P.M., B.M. Everett, T. Thuren, J.G. MacFadyen, W.H. Chang, C. Ballantyne, et al. 2017. Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine 377 (12): 1119\u20131131.","journal-title":"The New England Journal of Medicine"},{"issue":"10105","key":"1429_CR50","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker, P.M., J.G. MacFadyen, T. Thuren, B.M. Everett, P. Libby, R.J. Glynn, et al. 2017. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 390 (10105): 1833\u20131842.","journal-title":"Lancet."},{"key":"1429_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.critrevonc.2017.06.002","volume":"116","author":"RD Dolan","year":"2017","unstructured":"Dolan, R.D., S.T. McSorley, P.G. Horgan, B. Laird, and D.C. McMillan. 2017. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. Critical Reviews in Oncology\/Hematology 116: 134\u2013146.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"1429_CR52","doi-asserted-by":"publisher","first-page":"X158","DOI":"10.1093\/annonc\/mdx676.010","volume":"28","author":"I Wahid","year":"2017","unstructured":"Wahid, I. 2017. The role of neuropeptide y in cancer-associated anorexia and its correlation with interleukin-1 beta. Annals of Oncology 28: X158.","journal-title":"Annals of Oncology"},{"issue":"6","key":"1429_CR53","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00520-016-3553-z","volume":"25","author":"DR Fogelman","year":"2017","unstructured":"Fogelman, D.R., J. Morris, L. Xiao, M. Hassan, S. Vadhan, M. Overman, S. Javle, R. Shroff, G. Varadhachary, R. Wolff, L. Vence, A. Maitra, C. Cleeland, and X.S. Wang. 2017. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Supportive Care in Cancer 25 (6): 1809\u20131817.","journal-title":"Supportive Care in Cancer"},{"key":"1429_CR54","first-page":"629","volume":"6","author":"EM de Matos-Neto","year":"2015","unstructured":"de Matos-Neto, E.M., J.D. Lima, W.O. de Pereira, R.G. Figueredo, D.M. Riccardi, K. Radloff, et al. 2015. Systemic inflammation in cachexia - is tumor cytokine expression profile the culprit? Frontiers in Immunology 6: 629.","journal-title":"Frontiers in Immunology"},{"key":"1429_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.nut.2016.11.008","volume":"35","author":"H Jager-Wittenaar","year":"2017","unstructured":"Jager-Wittenaar, H., P.U. Dijkstra, G. Dijkstra, J. Bijzet, J.A. Langendijk, B. van der Laan, et al. 2017. High prevalence of cachexia in newly diagnosed head and neck cancer patients: An exploratory study. Nutrition. 35: 114\u2013118.","journal-title":"Nutrition."},{"issue":"8","key":"1429_CR56","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota, J., A. Vitale, A. Insalaco, P. Sfriso, G. Lopalco, G. Emmi, et al. 2018. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: A nationwide multicenter retrospective observational study. Clinical Rheumatology 37 (8): 2233\u20132240.","journal-title":"Clinical Rheumatology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-021-01429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-021-01429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-021-01429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:15:03Z","timestamp":1675210503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-021-01429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s10753-021-01429-8","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Approved by all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}